Windtree Therapeutics (WINT) is Initiated by H.C. Wainwright to Buy, Price Target at $8

Windtree Therapeutics (WINT) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $8. H.C. Wainwright advised their investors in a research report released on Apr 22, 2016.

Windtree Therapeutics

Leave a Reply

Windtree Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Windtree Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.